Form 4: Tandem Diabetes Care Director Increases Stake Through RSU Vesting and New Grant

Peyton R. Howell, a Director at Tandem Diabetes Care Inc., reported the acquisition of 4,387 shares of common stock following the vesting of restricted stock units and received a new grant of 8,759 restricted stock units.

Summary

• Peyton R. Howell, a Director of Tandem Diabetes Care Inc. (TNDM), reported transactions on May 21 and May 22, 2025.
• On May 22, 2025, Mr. Howell acquired 4,387 shares of Tandem Diabetes Care common stock at a price of $20.64 per share, resulting from the exercise/conversion of previously granted restricted stock units (RSUs).
• Following this transaction, Mr. Howell beneficially owns 21,077 shares of common stock directly.
• The 4,387 RSUs that converted to common stock were awarded on May 22, 2024, under the company's 2023 Long-Term Incentive Plan and vested on their one-year anniversary.
• On May 21, 2025, Mr. Howell was awarded a new grant of 8,759 restricted stock units (RSUs) under the 2023 Plan.
• Each RSU represents a contingent right to receive one share of common stock or cash, at the Issuer's discretion.
• The newly awarded 8,759 RSUs will vest on the one-year anniversary of their grant date, subject to the terms of the 2023 Plan.

Sentiment

Score: 5

Explanation: The document reports routine insider transactions (RSU vesting and new grant) which are neutral in sentiment, reflecting standard compensation practices rather than significant positive or negative news.

Positives

• The director's acquisition of common stock through RSU vesting increases their direct ownership in the company, aligning their interests with shareholders.
• The new grant of 8,759 restricted stock units indicates continued incentive and commitment of the director to the company's long-term performance.

Future Outlook

The new RSU grant to the director suggests a continued long-term incentive structure for key personnel, aligning their future compensation with the company's stock performance.

Industry Context

This Form 4 filing details routine insider equity transactions, which are common in publicly traded companies as part of executive and director compensation plans. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The director's increased direct ownership aligns their interests more closely with shareholders. The new RSU grant provides ongoing incentive for the director to contribute to the company's long-term value creation.

Next Steps

• The 8,759 Restricted Stock Units granted on May 21, 2025, are expected to vest on their one-year anniversary, subject to the terms of the 2023 Long-Term Incentive Plan.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Stock Ownership, Director, Equity Compensation, SEC Filing